SOURCE: Market Pulse

May 10, 2007 08:30 ET

Market Pulse Breaking News Alert for Thursday, May 10, 2007: HBSC - U.S. Patent Office Issues Human BioSystems Patent #7,202,020 - Compositions, Methods and Apparatuses for Preserving Platelets!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - May 10, 2007) - Market Pulse News Alert for this AM, Stocks to Watch are: Human BioSystems, Inc. (OTCBB: HBSC), Research In Motion Ltd. (NASDAQ: RIMM), Foster Wheeler Ltd. (NASDAQ: FWLT) and 24/7 Real Media Inc. (NASDAQ: TFSM).

Investors need to be watching Human BioSystems, Inc. (OTCBB: HBSC) this AM! Human Biosystems, Inc. is a leader in the development of preservation platform technologies that provide safe, high quality, and longer shelf lives for organs, tissue, cells and other biomaterials that are used in saving lives. Human BioSystems' proprietary preservation systems for initial products consist of non-toxic liquid solutions, proprietary protocols and solutions. These systems do not employ toxic preservatives or special cryogenic techniques or complex equipment. HBSC specializes in the development of proprietary above zero (HBS-AZ) and below zero (HBS-BZ) organ and tissue preservation systems and methods for preserving blood platelets. HBSC has five issued patents (with others pending) for technologies that preserve platelets and organs such as the kidney, heart, liver, and lung. The company's unique patent-pending technology could double the storage period for platelets, may dramatically reduce bacterial growth and may maintain better platelet functionality. The company has been successful in preserving blood platelets for ten days under refrigeration while maintaining cell structure and morphology, which has never been done before to HBSC's knowledge. HBSC is expected to be a major supplier to the industry with their improved platelet storage technology. HBSC's technology and equipment may allow blood centers and hospitals to recover more than $500 million in lost revenue annually in North America, Western Europe and Japan. The company's target customers include blood banks, hospitals, clinics, and similar organizations. Human BioSystems is seeking strategic partners for the preservation technology and licensee of the HBS-AZ preservation solution for organs preservation. Terms will include license fees and royalty for marketing and distribution rights. The company estimates a multi-billion dollar market demand for its platelet and organ preservation system coupled with the post-transplant technology. HBSC is looking for additional products that are close to commercialization to add to its pipeline. Human Biosystems' wholly owned subsidiary HBS BioEnergy develops the bioenergy business which includes the two ethanol fuel production facility projects to be acquired from EXL III Group Corporation pursuant to the Letter of Intent mentioned in their press release dated July 27, 2006. HBS BioEnergy recently formed a joint venture with Visalia based Dairy Development Group and Agrimass Enviro-Energy to build an Energy Park in the San Joaquin Valley of California. The Energy Park will utilize waste from surrounding dairies to provide the power needed to fuel a proposed ethanol plant to be located on site. Human Biosystems is poised to become a significant player in the biomedical and bioenergy industries! HBSC has had several excellent news announcements out lately and one again before today's bell announcing the U.S. Patent Office has now issued patent number 7,202,020 to HBSC for this patent entitled "Compositions, Methods and Apparatuses for Preserving Platelets." The company has now received five U.S. patents related to organ, platelet and biological material preservation! This could be great news for investors!

Human BioSystems (OTCBB: HBSC), developer of preservation platforms for organs, blood platelets and other biomaterials, announced in a press release dated January 22, 2007 that the U.S. Patent Office will allow the company's fifth patent. The U.S. Patent Office has now issued patent number 7,202,020 to HBSC for this patent entitled "Compositions, Methods and Apparatuses for Preserving Platelets."

HBSC has now received five U.S. patents related to organ, platelet and biological material preservation. HBSC' intellectual property portfolio consists of the following patents:

1. Methods and Apparatus for Preserving Biological Materials - U.S. Patent #6,413,713

2. Methods and Apparatuses for Preserving Platelets - U.S. Patent #6,828,090

3. Methods and Solutions for Storing Donor Organs - U.S. Patent #7,029,839

4. Preservation of Blood Platelets with Citrate - U.S. Patent #7,083,910

5. Compositions, Methods and Apparatuses for Preserving Platelets - U.S. Patent #7,202,020

Four of the five patents issued to HBSC relate to the preservation of blood platelets, a blood component critical to cancer patients that have undergone chemotherapy/radiation treatments. Platelet infusions are necessary for a period of time following such cancer treatments to maintain adequate platelet counts. The lack of platelets could increase the chances of bleeding.

David Winter, MD and President of Human BioSystems, said, "HBSC intends to extend the preservation time of platelets beyond current standards while maintaining quality and safety by utilizing patented cooling methods not achieved by others thus far in the commercial blood banking industry. If successful, this could result in hundreds of millions of dollars in savings to blood centers and hospitals worldwide."

HBSC is headquartered in Palo Alto, California with research facilities in Michigan.

Stocks in the news and acting well as of late include: Research In Motion Ltd. (NASDAQ: RIMM), Foster Wheeler Ltd. (NASDAQ: FWLT) and 24/7 Real Media Inc. (NASDAQ: TFSM).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Human BioSystems compensation from the company: six hundred seventy five thousand free trading shares of stock in Human BioSystems already received from the company. In addition, MP in the open market previously purchased one hundred thousand shares of stock in Human BioSystems for a total purchase price of eight thousand forty dollars. To date, MP has sold four hundred thousand shares of stock in Human BioSystems for proceeds totaling forty four thousand five hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information